Revium Rx 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
RVRC
Revium RxRevium Rx reports continued R&D progress in its Nano-Mupirocin program but faces significant financial challenges, including a substantial accumulated deficit and doubts about its going concern status.